Open access
Open access
Powered by Google Translator Translator

Oncology (all articles)

Systematic Review | An evidence-base for the implementation of hospital-based palliative care programs in routine cancer practice

19 Jul, 2023 | 14:23h | UTC

An evidence-base for the implementation of hospital-based palliative care programs in routine cancer practice: A systematic review – Palliative Medicine

 

IARC, WHO agency, identifies aspartame as potentially carcinogenic but probably safe within established acceptable daily intake

18 Jul, 2023 | 13:58h | UTC

News Release: Aspartame hazard and risk assessment results released – World Health Organization

Commentaries:

Expert reaction to IARC and JEFCA summary on aspartame – Science Media Centre

Does artificial sweetener aspartame really cause cancer? What the WHO listing means for your diet soft drink habit – The Conversation

Aspartame Hazard and Risk Assessment Results Released by IARC and JECFA – The ASCO Post

 

Single-arm study | Pembrolizumab plus Lenvatinib shows potential as first-line treatment for advanced non-clear-cell renal cell carcinoma

17 Jul, 2023 | 13:33h | UTC

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

 

TTMV-HPV DNA testing | Promising diagnostic and surveillance tool for HPV-linked oropharyngeal cancer

17 Jul, 2023 | 13:25h | UTC

Performance of Liquid Biopsy for Diagnosis and Surveillance of Human Papillomavirus–Associated Oropharyngeal Cancer – JAMA Otolaryngology–Head & Neck Surgery (free for a limited period)

Invited Commentary: Circulating Human Papillomavirus Tumor DNA—Ready for Prime Time? –  – JAMA Otolaryngology–Head & Neck Surgery (free for a limited period)

 

Review | Guiding the use of invasive cardiac interventions in patients with advanced malignancies

17 Jul, 2023 | 13:23h | UTC

Invasive Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: A Conceptual Framework: JACC: CardioOncology State-of-the-Art Review – JACC: CardioOncology

 

Consensus Paper | Ten recommendations for sarcoma surgery

14 Jul, 2023 | 12:49h | UTC

Ten recommendations for sarcoma surgery: consensus of the surgical societies based on the German S3 guideline “Adult Soft Tissue Sarcomas” – Langenbeck’s Archives of Surgery

 

RCT | Efficacy of different treatment regimens in unresectable colorectal cancer liver metastases

14 Jul, 2023 | 12:42h | UTC

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Cohort Study | Long-term cancer survivors face higher risk of noncancer death

14 Jul, 2023 | 12:38h | UTC

Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US – JAMA Network Open

 

Commentary on Twitter

 

Phase 2 Study | BRAF-MEK inhibition in BRAF-mutated papillary craniopharyngiomas leads to tumor volume reduction

13 Jul, 2023 | 13:02h | UTC

BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Rare Brain Tumor Responds to Targeted Tumor Treatment with ‘Unprecedented’ Success – Mass General Brigham

 

Commentary on Twitter

 

2023 ETA clinical practice guidelines for thyroid nodule management

12 Jul, 2023 | 13:48h | UTC

2023 European Thyroid Association clinical practice guidelines for thyroid nodule management – European Thyroid Journal

 

The 2023 Bethesda System for reporting thyroid cytopathology

12 Jul, 2023 | 13:46h | UTC

The 2023 Bethesda System for Reporting Thyroid Cytopathology – Thyroid

 

RCT | Atezolizumab in platinum-ineligible NSCLC elevates median survival to 10.3 months vs. 9.2 months with chemotherapy

10 Jul, 2023 | 13:33h | UTC

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study – The Lancet (link to abstract – $ for full-text)

News Release: Immunotherapy for ‘difficult to treat’ lung cancer patients improves long-term survival – University College London

 

RCT | Perioperative nivolumab plus chemotherapy increases pathological response vs. chemotherapy alone in stage III NSCLC

10 Jul, 2023 | 13:27h | UTC

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Addition of Neoadjuvant Nivolumab to Platinum-Based Chemotherapy in Stage III NSCLC – The ASCO Post

 

Commentary on Twitter

 

RCT | Brachytherapy alone sufficient for intermediate-risk prostate cancer, no FFP improvement with additional EBRT

7 Jul, 2023 | 16:06h | UTC

Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

News Release: Addition of EBRT to brachytherapy did not improve outcomes for men with intermediate-risk prostate cancer, brachytherapy alone remains standard of care – NRG Oncology

 

RCT | FOLFOXIRI-Bevacizumab shows promise as first-line treatment in unresectable colorectal cancer metastases

5 Jul, 2023 | 01:02h | UTC

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group – The Lancet Oncology (link to abstract – $ for full-tetxt)

 

Scoping Review | High correlation of positive outcomes in oncology meta-analyses with industry funding

3 Jul, 2023 | 14:21h | UTC

Scoping Review: High Correlation of Positive Outcomes in Oncology Meta-analyses with Industry Funding – JAMA Network Open

 

Consensus Paper | Colorectal neuroendocrine tumors

30 Jun, 2023 | 14:45h | UTC

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours – Journal of Neuroendocrinology

 

SR | Drivers of emergency department use among oncology patients in the era of novel cancer therapeutics

30 Jun, 2023 | 14:35h | UTC

Drivers of Emergency Department Use Among Oncology Patients in the Era of Novel Cancer Therapeutics: A Systematic Review – The Oncologist

 

FIGO staging of endometrial cancer: 2023

29 Jun, 2023 | 13:53h | UTC

FIGO staging of endometrial cancer: 2023 – Gynecology & Obstetrics

 

Perspective | Ensuring ethical postprogression therapy for patients in randomized trial control arms

28 Jun, 2023 | 13:16h | UTC

Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms – Journal of Clinical Oncology

 

Commentary on Twitter

 

RCT | Total breast reconstruction with autologous fat transfer using an expansion device vs implants in patients with breast cancer

28 Jun, 2023 | 13:12h | UTC

Effect of Total Breast Reconstruction With Autologous Fat Transfer Using an Expansion Device vs Implants on Quality of Life Among Patients With Breast Cancer: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)

See also: Visual Abstract

Author Interview: Effect of Breast Reconstruction With Autologous Fat Transfer vs Implants on Quality of Life – JAMA

 

SR | Medically assisted hydration in palliative care: uncertain effects on quality of life and survival

27 Jun, 2023 | 13:47h | UTC

Summary: The Cochrane Review analyzed Randomized Controlled Trials (RCTs) to evaluate the impact of Medically Assisted Hydration (MAH) on the Quality of Life (QoL) and survival of adults receiving palliative care. A total of four studies involving 422 participants, all diagnosed with advanced cancer, were considered. Two studies compared MAH with placebo, and two compared it with standard care.

The primary outcome was QoL, assessed through validated scales, with survival and adverse events being secondary outcomes. Mean differences (MD) and risk ratios (RR) were calculated for continuous and dichotomous outcomes, respectively. However, results were inconclusive due to a very low certainty of evidence. Hence, it is unclear whether MAH improves QoL, prolongs survival, or leads to adverse events when compared to placebo or standard care.

The findings are only applicable to inpatients with advanced cancer at the end of life and do not transfer to other adults in palliative care with non-cancer, dementia, or neurodegenerative diseases, or those with an extended prognosis. The lack of high-quality evidence leaves clinicians to make decisions based on perceived benefits and harms for individual circumstances.

Article: Medically assisted hydration for adults receiving palliative care – Cochrane Library

 

M-A | Effectiveness of physical therapy in axillary web syndrome after breast cancer

27 Jun, 2023 | 13:28h | UTC

Effectiveness of physical therapy in axillary web syndrome after breast cancer: a systematic review and meta-analysis – Supportive Care in Cancer

 

Perspective | Early-stage lung cancer: using circulating tumor DNA to get personal

26 Jun, 2023 | 00:38h | UTC

Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal – Journal of Clinical Oncology

 

Review | How to treat diffuse large B-cell lymphoma: oncologic and cardiovascular considerations

26 Jun, 2023 | 00:33h | UTC

How to Treat Diffuse Large B-Cell Lymphoma: Oncologic and Cardiovascular Considerations – JACC: CardioOncology

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.